CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the
The JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:30 am ET.
The fireside chat will be webcast and an archived recording will be available for replay in the Investors section of the Madrigal website after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.
Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$243.89 |
| Daily Change: | -2.11 -0.86 |
| Daily Volume: | 215,658 |
| Market Cap: | US$5.290B |
August 07, 2024 May 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
